Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Syndax Pharmaceuticals, Inc. (SNDX) had Normalized Pre-Tax Income of $-49.36M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$72.79M |
|
$-49.36M |
|
$3.21M |
|
$69.58M |
|
$112.78M |
|
$-39.99M |
|
$-9.37M |
|
$-49.36M |
|
|
Normalized Pre-Tax Income |
$-49.36M |
$-49.36M |
|
$-49.36M |
|
$-49.36M |
|
$-49.36M |
|
$-39.99M |
|
$-40.52M |
|
88.99M |
|
88.99M |
|
$-0.55 |
|
$-0.55 |
|
| Balance Sheet Financials | |
$675.04M |
|
$0.21M |
|
$28.61M |
|
$703.65M |
|
$99.68M |
|
$588.12M |
|
$588.88M |
|
$688.55M |
|
$15.10M |
|
$15.10M |
|
$15.10M |
|
89.15M |
|
| Cash Flow Statement Financials | |
$-80.62M |
|
$21.48M |
|
$260.69M |
|
$135.03M |
|
$336.58M |
|
$201.55M |
|
$26.07M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.77 |
|
-- |
|
-- |
|
0.97 |
|
38.95 |
|
95.59% |
|
-54.95% |
|
-54.95% |
|
-- |
|
-67.82% |
|
-67.82% |
|
$-80.66M |
|
-- |
|
-- |
|
-- |
|
0.10 |
|
0.10 |
|
1.04 |
|
86.71 |
|
-326.93% |
|
-326.93% |
|
-7.02% |
|
-8.18% |
|
$0.17 |
|
$-0.91 |
|
$-0.91 |
|